Across TCGA pan-cancer cohorts, HCN2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HCN2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HCN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HCN2 expression acts as an unfavorable survival marker.
HNSC and SKCM are the cancer types where HCN2 Mutation most reproducibly stratifies survival.